44 related articles for article (PubMed ID: 36437569)
1. Utility of combined gadoxetic acid and ferumoxytol-enhanced liver MRI for preoperative detection of colorectal cancer liver metastases: a pilot study.
Carney BW; Gholami S; Fananapazir G; Sekhon S; Lamba R; Loehfelm TW; Wilson MD; Corwin MT
Acta Radiol; 2023 Apr; 64(4):1357-1362. PubMed ID: 36437569
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic performance of abbreviated gadoxetic acid-enhanced magnetic resonance protocols with contrast-enhanced computed tomography for detection of colorectal liver metastases.
Ozaki K; Ishida S; Higuchi S; Sakai T; Kitano A; Takata K; Kinoshita K; Matta Y; Ohtani T; Kimura H; Gabata T
World J Radiol; 2022 Oct; 14(10):352-366. PubMed ID: 36340439
[TBL] [Abstract][Full Text] [Related]
3. Clinical added value of MRI to CT in patients scheduled for local therapy of colorectal liver metastases (CAMINO): study protocol for an international multicentre prospective diagnostic accuracy study.
Görgec B; Hansen I; Kemmerich G; Syversveen T; Abu Hilal M; Belt EJT; Bisschops RHC; Bollen TL; Bosscha K; Burgmans MC; Cappendijk V; De Boer MT; D'Hondt M; Edwin B; Gielkens H; Grünhagen DJ; Gillardin P; Gobardhan PD; Hartgrink HH; Horsthuis K; Kok NFM; Kint PAM; Kruimer JWH; Leclercq WKG; Lips DJ; Lutin B; Maas M; Marsman HA; Morone M; Pennings JP; Peringa J; Te Riele WW; Vermaas M; Wicherts D; Willemssen FEJA; Zonderhuis BM; Bossuyt PMM; Swijnenburg RJ; Fretland ÅA; Verhoef C; Besselink MG; Stoker J;
BMC Cancer; 2021 Oct; 21(1):1116. PubMed ID: 34663243
[TBL] [Abstract][Full Text] [Related]
4. MRI in addition to CT in patients scheduled for local therapy of colorectal liver metastases (CAMINO): an international, multicentre, prospective, diagnostic accuracy trial.
Görgec B; Hansen IS; Kemmerich G; Syversveen T; Abu Hilal M; Belt EJT; Bosscha K; Burgmans MC; Cappendijk VC; D'Hondt M; Edwin B; van Erkel AR; Gielkens HAJ; Grünhagen DJ; Gobardhan PD; Hartgrink HH; Horsthuis K; Klompenhouwer EG; Kok NFM; Kint PAM; Kuhlmann K; Leclercq WKG; Lips DJ; Lutin B; Maas M; Marsman HA; Meijerink M; Meyer Y; Morone M; Peringa J; Sijberden JP; van Delden OM; van den Bergh JE; Vanhooymissen IJS; Vermaas M; Willemssen FEJA; Dijkgraaf MGW; Bossuyt PM; Swijnenburg RJ; Fretland ÅA; Verhoef C; Besselink MG; Stoker J;
Lancet Oncol; 2024 Jan; 25(1):137-146. PubMed ID: 38081200
[TBL] [Abstract][Full Text] [Related]
5. Improved Detection of Bone Metastases in Children and Young Adults with Ferumoxytol-enhanced MRI.
Rashidi A; Baratto L; Theruvath AJ; Greene EB; Jayapal P; Hawk KE; Lu R; Seekins J; Spunt SL; Pribnow A; Daldrup-Link HE
Radiol Imaging Cancer; 2023 Mar; 5(2):e220080. PubMed ID: 36999999
[TBL] [Abstract][Full Text] [Related]
6. Qualitative and quantitative parameters on hepatobiliary phase of gadoxetic acid-enhanced MR imaging for predicting pathological response to preoperative systemic therapy in colorectal liver metastases.
Gu XL; Cui Y; Wang K; Xing Q; Li XT; Zhu HT; Li ZW; Sun YS
Eur J Radiol; 2022 Dec; 157():110572. PubMed ID: 36327859
[TBL] [Abstract][Full Text] [Related]
7. Clinical Significance of Liver MR Imaging.
Ichikawa S; Goshima S
Magn Reson Med Sci; 2023 Apr; 22(2):157-175. PubMed ID: 36725068
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Performance of Contrast Enhanced CT Alone or in Combination with (Non-)Enhanced MRI for Colorectal Liver Metastasis.
Qiu QS; Zhu K; Wang JH; Chen XS; Wang WT; Dong SY; Sun W; Rao SX
Acad Radiol; 2023 Sep; 30(9):1856-1865. PubMed ID: 36481127
[TBL] [Abstract][Full Text] [Related]
9. Quantitative evaluation of functional liver reserve using the liver-to-spleen ΔR
Eitoku S; Fujiwara Y; Mio M
Acta Radiol; 2023 May; 64(5):1738-1746. PubMed ID: 36380498
[TBL] [Abstract][Full Text] [Related]
10. What Does the Boxed Warning Tell Us? Safe Practice of Using Ferumoxytol as an MRI Contrast Agent.
Varallyay CG; Toth GB; Fu R; Netto JP; Firkins J; Ambady P; Neuwelt EA
AJNR Am J Neuroradiol; 2017 Jul; 38(7):1297-1302. PubMed ID: 28495944
[TBL] [Abstract][Full Text] [Related]
11. Gadoxetic acid (Primovist®) beyond the characterization of hepatic lesions in MRI: the case of biliary leaks.
Salgado-Parente A; Gil-Boronat A; Canales Lachen E; Muñoz Beltrán M
Rev Esp Enferm Dig; 2023 Aug; 115(8):459-460. PubMed ID: 36263828
[TBL] [Abstract][Full Text] [Related]
12. Clinical translation of ferumoxytol-based vessel size imaging (VSI): Feasibility in a phase I oncology clinical trial population.
Fredrickson J; Serkova NJ; Wyatt SK; Carano RA; Pirzkall A; Rhee I; Rosen LS; Bessudo A; Weekes C; de Crespigny A
Magn Reson Med; 2017 Feb; 77(2):814-825. PubMed ID: 26918893
[TBL] [Abstract][Full Text] [Related]
13. Pretherapy Ferumoxytol-enhanced MRI to Predict Response to Liposomal Irinotecan in Metastatic Breast Cancer.
Ravi H; Arias-Lorza AM; Costello JR; Han HS; Jeong DK; Klinz SG; Sachdev JC; Korn RL; Raghunand N
Radiol Imaging Cancer; 2023 Mar; 5(2):e220022. PubMed ID: 36734848
[TBL] [Abstract][Full Text] [Related]
14. Gadoxetic Acid in MRI: A Five-Year Experience at a High-Complexity Hospital in Colombia.
Pimiento Figueroa J; Lopera Valle JS; Gomez Urrego AM; García Gómez V; Gonzalez M; Huertas Duran C
Cureus; 2024 Apr; 16(4):e58150. PubMed ID: 38741819
[TBL] [Abstract][Full Text] [Related]
15. Liver MRI in patients scheduled for local therapy of colorectal liver metastases.
Vernuccio F
Lancet Oncol; 2024 Jan; 25(1):9-10. PubMed ID: 38081199
[No Abstract] [Full Text] [Related]
16. Guide to use of ferumoxytol for hepatic vascular assessment as part of dual contrast MRI.
Shah R; VanSyckel A; Popescu AR; Rigsby CK; Griffin LM
Pediatr Radiol; 2023 Oct; 53(11):2180-2187. PubMed ID: 37599288
[TBL] [Abstract][Full Text] [Related]
17. Enhancing Clinical Decision-Making: The Impact of Liver Contrast-enhanced MRI on Local Treatment Plans for Colorectal Liver Metastases.
Lin YM
Radiol Imaging Cancer; 2024 Jan; 6(1):e239023. PubMed ID: 38240670
[No Abstract] [Full Text] [Related]
18. Radiomodulating Properties of Superparamagnetic Iron Oxide Nanoparticle (SPION) Agent Ferumoxytol on Human Monocytes: Implications for MRI-Guided Liver Radiotherapy.
Shurin MR; Kirichenko VA; Shurin GV; Lee D; Crane C; Kirichenko AV
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610996
[TBL] [Abstract][Full Text] [Related]
19. Unveiling the next generation of MRI contrast agents: current insights and perspectives on ferumoxytol-enhanced MRI.
Si G; Du Y; Tang P; Ma G; Jia Z; Zhou X; Mu D; Shen Y; Lu Y; Mao Y; Chen C; Li Y; Gu N
Natl Sci Rev; 2024 May; 11(5):nwae057. PubMed ID: 38577664
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro and in vivo Evaluation of Different Iron Oxide-Based Contrast Agents to Promote Clinical Translation in Compliance with Patient Safety.
Unterweger H; Janko C; Folk T; Cicha I; Kovács N; Gyebnár G; Horváth I; Máthé D; Zheng KH; Coolen BF; Stroes E; Szebeni J; Alexiou C; Dézsi L; Lyer S
Int J Nanomedicine; 2023; 18():2071-2086. PubMed ID: 37113796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
